Selective express tumor diagnostic with narrow band nanophotonic structures (Q3128691): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Changed label, description and/or aliases in fr: translated_label) |
||
| label / fr | label / fr | ||
Diagnostic de tumeur express sélectif avec des structures nanophotoniques à bande étroite | |||
Revision as of 13:30, 30 November 2021
Project Q3128691 in Greece
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Selective express tumor diagnostic with narrow band nanophotonic structures |
Project Q3128691 in Greece |
Statements
92,000.0 Euro
0 references
10 October 2017
0 references
9 October 2019
0 references
ΝΑΝΟΤΥΠΟΣ ΟΕ
0 references
40°54'2.41"N, 22°57'19.80"E
0 references
35°11'2.58"N, 24°58'5.63"E
0 references
his EXODIAGNOS project proposal addresses the development of novel approach for tumor diagnostics. A new selective, early-stage, non-invasive, express cancer diagnostic procedure utilizing exosomal vesiclesand their content recognition by specially designed narrow bandwidth active/passive nano- andmicrophotonic sensors will be proposed for clinical trials.Our approach is based on three recently suggested novelties.(i) Recognition of exosomal biomarkers surface and intravesicular proteins and mRNA and DNA nucleic acids as tumor markers.(ii) Amplitude and phase detection methods using narrow band localized plasmonic resonances and resonances in microcavities, to make a breakthrough in the sensitivity and selectivity of the respective bioand environmental sensors.(iii) Ultra-sensitive detection promised by Active Plasmonic Platform (quantum emitters coupled with the plasmonic nanoresonators and/or microresonators). (Greek)
0 references
his EXODIAGNOS project proposal addresses the development of novel approach for tumor diagnostics. A new selective, early-stage, non-invasive, express cancer diagnostic procedure utilising exosomal vesiclesand their content recognition by specially designed narrow bandwidth active/passive nano- andmicrophotonic sensors will be proposed for clinical trials.Our approach is based on three recently suggested Novelties.(i) Recognition of exosomal biomarkers surface and intravesicular proteins and mRNA and DNA nucleic acids as tumor markers.(ii) amplitude and phase detection methods using narrow band localised plasmonic resonances and resonances in microcavities, to make a breakthrough in the sensitivity and selectivity of the respective bioand environmental sensors.(iii) Ultra-sensitive detection promised by Active plasmonic Platform (quantum emitters coupled with the plasmonic nanoresonators and/or microresonators). (English)
30 September 2021
0 references
Identifiers
5.017.617
0 references